POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (6.11.2021, 1:23pm CEST, WHO):   U.S. 22,053    India 91,702    Brazil 85,748    France 5,358    Turkey 6,454    Russia 11,699    The United Kingdom 7,312    Italy 2,198    Argentina 29,757    Spain 2,162    Germany 3,187    Columbia 24,233    Iran 12,398    Mexico 3,855    Ukraine 1,785    Peru 3,270    Indonesia 8,892    South Africa 9,147    The Netherlands 1,791    Chile 7,708    Canada 1,388    Philippines 7,485    Iraq 4,684    Sweden 1,175    Pakistan 1,303    Bangladesh 2,576    Japan 2,112    Malaysia 5,671    Nepal 2,874    United Arab Emirates 2,190    Saudi Arabia 1,286    Bolivia 3,839    Paraguay 3,100    Tunisia 2,373    Costa Rica 2,187    Uruguay 3,427    Kuwait 1,709    Dominican Republic 1,141    Bahrain 1,034    Venezuela 1,464    Oman 1,640    Sri Lanka 2,738    Thailand 2,290    Cuba 1,158    Zambia 2,146    Afghanistan 1,824    Mongolia 1,460    Namibia 1,045    Uganda 1,438    China 290    Singapore 13    New Zealand 5    Australia 16    South Korea 556   

'Mad cow' ban lifted to allow UK blood plasma to be used for life-saving treatments

Christian Fernsby |
Thousands more critically ill patients will soon be able to benefit from life-saving treatments made from UK-sourced blood plasma, as the government lifts a decades-old ban on donations of plasma in the UK being used to manufacture some medicines.

Article continues below




The medicines, known as immunoglobulins, are manufactured from blood plasma donated by the public and are used to treat several serious diseases and conditions, such as for those with severely reduced immune systems due to long-term cancer treatment or people with antibody deficiencies.

By lifting the ban in England, the government can start to use plasma donations from UK blood donors to manufacture these life-saving medicines for NHS patients.

The ban was introduced in 1998 in response to concerns over the spread of a human variant of BSE, known as ‘mad cow’s disease’, called Creutzfeldt Jakob Disease. Experts in medicine safety at the independent Commission on Human Medicines (CHM) have now advised the use of UK-sourced plasma to manufacture these treatments is safe and can recommence supported by a set of robust safety measures.

Health Minister Lord Bethell said: "Following expert advice, I am pleased we are now able to lift this ban to help thousands of NHS patients access these potentially life-saving treatments as quickly as possible. The move will also help England become self-sufficient and we will not have to rely only on imports from other countries, ensuring every NHS patient can always access the treatments they need."

Convalescent plasma is currently being trialled in the UK for the treatment of COVID-19 and, if the results are positive, this would mean immunoglobulins from plasma donated in the UK could in future be used as immunoglobulins to treat coronavirus patients.

Up until now, the UK has depended on imports of blood plasma from other countries – mainly the US – to manufacture these treatments. Due to a large rise in global demand for immunoglobulins, both plasma and these treatments have experienced ongoing pressures on supply in the UK and around the world in recent years. The impact of the COVID-19 pandemic has also meant a significant drop in plasma donations from the US, further increasing pressures on supply.

The lifting of the ban will bolster the supply chain and improve the self-sufficiency of the UK in producing its own treatments. The government will also introduce a new condition to ensure UK plasma is used first for UK patients and not exported to meet contracts elsewhere.


What to read next

New rules for smoking near schools in New York State
Leading heart consultant: E-cigarettes and vaping 'disaster of the century'
FDA will ban many flavored e-cigarettes